US EditionFDA says it will be 'aggressive' in adopting artificial intelligence in its labs
- FDA Commissioner Martin Makary announced the completion of a generative AI pilot aimed at accelerating drug review, with rollout planned by June 30, 2025.
- The pilot follows recent layoffs that reduced FDA AI experts by 75%, which likely increased urgency for automating review tasks despite known AI error risks.
- Chief AI Officer Jeremy Walsh, formerly of Booz Allen Hamilton, will coordinate agency-wide AI integration, including the project called cderGPT co-developed with OpenAI.
- FDA staff reported that AI shortens scientific review tasks from three days to minutes, while Makary urged valuing scientists’ time and reducing non-productive busywork.
- The rapid AI adoption promises faster drug approvals but raises concerns about patient safety and the agency’s ability to fully understand AI model limitations.
Insights by Ground AI
Does this summary seem wrong?
34 Articles
34 Articles
All
Left
1
Center
6
Right
5
US FDA centres to deploy AI internally, following experimental run
The US Food and Drug Administration (FDA) said on Thursday all its centres will deploy artificial intelligence internally immediately, with full integration on June 30, following the completion of a new generative AI pilot for scientific reviewers.
·Johannesburg, South Africa
Read Full Article
Coverage Details
Total News Sources34
Leaning Left1Leaning Right5Center6Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
C 50%
R 42%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
